Introduction
Kaposi's sarcoma (KS) is one of the most frequent tumors in patients infected with HIV-1 (Masood et al., 1993; Ensoli and Gallo, 1995) . KS is a highly vascularized tumor that frequently involves skin and mucous membranes and is complicated by tumor associated edema and ulceration (Masood et al., 1993; Ensoli and Gallo, 1995) . Histologically, KS is characterized by the presence of complex spindle like cells which are believed to be endothelial in origin (Masood et al., 1993; Ensoli and Gallo, 1995) . One of the most intriguing aspects of KS is the role of various cytokines in its pathogenesis. In its early stages, KS is a polyclonal angioproliferative lesion which is driven in autocrine and paracrine fashion by the exuberant production of growth-promoting, inflammatory and angiogenic cytokines by KS spindle cells and surrounding stromal elements (Masood et al., 1993; Ensoli and Gallo, 1995) .
A number of cytokines have been implicated in the pathogenesis of KS, including transforming growth factor-b, IL-1, IL-6, oncostatin-M, platelet-derived growth factor, basic fibroblast growth factor and vascular endothelial growth factor (Masood et al., 1993; Ensoli and Gallo, 1995) . Recent studies indicate that IL-8/CXCL8 plays a pivotal role in the pathogenesis of KS as well (Masood et al., 2001; Wang et al., 2004) . IL-8 is the prototypical member of the C-X-C chemokine family and was initially identified as a chemo-attractant for neutrophils (Watanabe et al., 1989) but was subsequently shown to possess additional biological activities, including stimulation of angiogenesis and tumor growth (Koch et al., 1992; Sparmann and Bar-Sagi, 2004) . In nude mice xenograft model system, IL-8 expression has been implicated in the initiation of tumor-associated inflammation and neovascularization and shown to directly correlate with metastatic potential (Adams and Elliott, 2000) . A role for IL-8 in the pathogenesis of KS has been suggested by its high levels in the serum of KS patients as compared with matched controls and in the supernatant of AIDS-KS cell lines as compared with human umbilical vein endothelial cells (HUVECs) (Masood et al., 2001) . Antisense oligonucleotides and neutralizing antibodies against IL-8 were shown to inhibit KS cell growth, suggesting that it is an autocrine growth factor for these cells (Masood et al., 2001) .
Human herpesvirus 8 (HHV-8) or KS-associated herpesvirus (KSHV) is a g-2 herpesvirus that has been shown to be associated with all forms of KS (classical, iatrogenic, endemic and AIDS related) as well as a number of other neoplastic disorders, such as primary effusion lymphoma, multicentric Castleman's disease and angio-immunoblastic lymphadenopathy with dysproteinemia (Schulz, 1998; Dourmishev et al., 2003; Verma and Robertson, 2003) . HHV-8 infection of endothelial cells induces IL-8 production, which plays a crucial role in the angiogenic phenotype developed by HHV-8-infected endothelial cells in culture and upon implantation into SCID mice (Lane et al., 2002) . HHV-8 encodes for homologs of several known oncogenes, chemokines, cytokines and their receptors. However, a number of these proteins have evolved to perform functions critical to the life cycle of the virus and have acquired novel functional attributes not possessed by their cellular homologs (Moore and Chang, 2003) . One such protein with unique functional properties is encoded by the open reading frame K13 (also called orf71). The K13 protein contains two homologous copies of a death effector domain (DED) that is also present in the prodomain of caspase 8 (also known as FLICE). K13 protein was originally believed to protect virally infected cells from death receptor-induced apoptosis by blocking the recruitment and/or activation of caspase 8/FLICE and, as such, is commonly referred to as viral FLICE inhibitory proteins (vFLIP) (Bertin et al., 1997; Hu et al., 1997; Thome et al., 1997) . We subsequently showed that K13 protein also possesses the ability to activate the NF-kB pathway (Chaudhary et al., 1999b; Liu et al., 2002) . As K13 is one of the few HHV-8-encoded proteins to be expressed in latently infected KS spindle cells (Sarid et al., 1998; Sturzl et al., 1999) , in this report we have investigated its role in the upregulation of IL-8 expression and secretion and the signaling pathways involved in this process.
Results

K13-upregulates IL-8 expression
It has been previously reported that infection of human vascular endothelial cells with HHV-8 leads to increased production of IL-8, which not only serves as an autocrine growth factor but also promotes angiogenesis (Masood et al., 2001; Lane et al., 2002) . As K13 is one of the few HHV-8-encoded proteins to be expressed in cells latently infected with HHV-8, we began by testing whether expression of K13 in human vascular endothelial cells can mimic the effect of HHV-8 infection on IL-8 production. For this purpose, we used retroviralmediated gene transfer to generate polyclonal populations of HUVEC cells expressing either an empty vector or K13. The retroviral vectors also expressed a green fluorescent protein (EGFP) from an internal ribosomal entry site. We achieved more than 80% transduction efficiency after a single round of infection with the recombinant viruses, as determined by EGFP expression 72 h postinfection (not shown). Next, we examined the secretion of IL-8 in the supernatant of control vector-or K13-expressing HUVEC cells using ELISA. As shown in Figure 1a , K13-expressing HUVEC cells were found to express 10-fold higher levels of IL-8 as compared to control vector-expressing cells. In order to rule out the possibility that K13-induced IL-8 production was limited to HUVEC cells, we examined the level of IL-8 in the supernatant of Hela cells, which stably expressed either an empty vector or K13. Similar to the situation with HUVEC cells, level of IL-8 was elevated more than 15-fold in K13-expressing Hela cells as compared to those expressing an empty vector (Figure 1b ).
K13 induces transcriptional activation of IL-8 promoter IL-8 gene is rapidly induced in response to proinflammatory cytokines and nuclear run-on assays have demonstrated that this induction is regulated at the level of gene transcription (Mukaida et al., 1994) . It has been previously demonstrated that the elements within the first 135 bp of the 5 0 flanking region of IL-8 gene regulate its transcriptional activation (Mori et al., 1998) . To determine the mechanism of IL-8 upregulation by K13, we examined the effect of K13 on the transcrip- tional activity of a luciferase reporter construct (Wu et al., 1997) containing the 5 0 flanking sequence of IL-8 promoter. We transfected the IL8-luc reporter plasmid into 293T cells along with an empty vector or an expression plasmid-encoding K13 and measured the luciferase activity in the cell lysates 28-30 h posttransfection. As shown in Figure 2a , transient transfection of K13 expression plasmid led to significant increase in IL-8 luciferase reporter activity as compared to transfection with an empty vector. As vFLIPs E8 from the Equine herpesvirus 2 and MC159L from the Molluscum contagiosum virus resemble K13 in possessing two DEDs, we tested the ability of these vFLIPs to activate the IL8-luc reporter activity. Interestingly, unlike K13, vFLIPs E8 and MC159L failed to activate the IL-8 promoter (Figure 2a ).
Role of NF-kB pathway in K13-induced IL-8 transcriptional activation
We have previously shown that K13 possesses the ability to activate the NF-kB pathway, a property not shared by vFLIPs E8 and MC159L (Chaudhary et al., 1999b) . Therefore, we next examined the role of the NF-kB pathway in K13-induced IL-8 transcriptional activation. We have previously generated two mutants of K13, 67AAA and 58AAA, which demonstrate partial and complete loss of the NF-kB-activating ability, respectively . In order to test the hypothesis that K13 activates the IL-8 promoter via NF-kB pathway, we tested the ability of wild-type and mutant K13 constructs to activate the IL8-luciferase reporter construct. Consistent with their NF-kB-activating ability , the triple mutant 58AAA demonstrated a complete lack of IL8 reporter activation while the mutant 67AAA retained partial ability to do so ( Figure 2b ). The above results suggested the involvement of the NF-kB pathway in K13-induced IL8 transcriptional activation.
In order to confirm the role of the NF-kB pathway in K13-induced IL-8 transcriptional activation, we used luciferase reporter constructs containing either the wildtype IL-8 promoter or its deletion mutant containing a 3-bp mutation in the NF-kB-binding site (Wu et al., 1997) . The expression of K13 led to an approximately 70-fold increase in luciferase reporter activity from the wild-type IL8-Luc promoter as compared to the expression of an empty vector ( Figure 2c ). The basal level of luciferase activity was markedly reduced when an IL-8 promoter containing a 3-bp mutation in the NFkB-binding site (IL-8-mNF-kB-Luc) was transfected into 293T cells along with an empty vector ( Figure 2c ). More importantly, there was no increase in the luciferase reporter activity when the IL-8-mNF-kB-Luc was coexpressed with K13, suggesting a critical role of NF-kB in both the basal and K13-induced IL-8 transcriptional activation (Figure 2c ). The experiment was performed as described for Figure 2a . (c) The NF-kB site in IL-8 promoter is critical for activation by K13. 293T cells were transfected with an empty vector, K13 or E8 (250 ng/ well) along with a wild-type IL-8 promoter luciferase construct or its mutant with a 3-bp mutation in the NF-kB-binding site (20 ng/ well). An RSV/LacZ (b-galactosidase) reporter construct (75 ng/ well) was included as a normalization control. The experiment was performed as described in Figure 2a . The values shown are averages (mean7s.e.) of one representative experiment out of three in which each transfection was performed in duplicate.
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K13 induces binding of specific transcription factors to IL-8 promoter
We next tested the hypothesis that K13 induces IL-8 expression by inducing the binding of specific transcription factors to the NF-kB-binding sites present in the IL-8 promoter. For this purpose, we generated nuclear extracts from Jurkat cells which stably express either K13 or an empty vector and used them in an electrophoretic mobility shift assay (EMSA). As shown in Figure 3a , nuclear extracts from K13-expressing Jurkat cells demonstrated significant DNA-binding activity on radiolabeled oligonucleotides-derived from the NF-kB-binding site present in IL-8 promoter. In contrast, no DNA-binding activity was observed when a mutant NF-kB-binding site from the IL-8 promoter was used in EMSA ( Figure 3a ) or when nuclear extracts from an empty vector-expressing cells were utilized ( Figure 3a ).
Nature and subunit composition of K13-induced transcription factors bound to IL-8 promoter
Recently an alternative (or non-canonical) pathway of NF-kB activation, which involves proteasome-mediated processing of p100/NF-kB2 into p52 subunit, has been described (Pomerantz and Baltimore, 2002) . K13 can activate the alternate NF-kB pathway via an IKK1-dependent and NIK-and IKK2-independent process (Matta and Chaudhary, 2004) . In order to determine the contribution of the classical vs alternate NF-kB pathway to K13-induced IL-8 promoter activation, we used a supershift assay to analyse the nature of the protein complexes bound to IL-8 promoter from nuclear extracts of K13-expressing Jurkat and 293T cells. This assay demonstrated that the two subunits of the classical NF-kB pathway, p65 and c-Rel, are the major components of the IL-8 promoter-bound NF-kB complexes induced by K13, with minor contribution from p50 subunit (Figure 3b and c) . Essentially similar results were obtained when nuclear extracts from K13-expressing K562 cells were used in EMSA with the exception that p65 and p50 subunits represented the major constituents of the NF-kB complex with minor contribution from the c-Rel subunit (Figure 3d ). Collectively, the above results support the hypothesis that K13 primarily activates the IL-8 promoter via the classical NF-kB pathway.
Role of individual subunits of the IKK complex in K13-induced IL-8 promoter activation K13 is known to associate with a 700 kDa multisubunit IKK complex, which consists of two catalytic subunits, IKK1/IKKa and IKK2/IKKb and a regulatory subunit, NEMO/IKKg . We tested the involvement of the individual components of the IKK complex in vFLIP K13-induced IL-8 promoter activity by using mouse embryonic fibroblast (MEF) cells deficient in IKK1, IKK2 and NEMO, respectively. As shown in Figure 4a , we observed significant IL-8 promoter activity by the expression of K13 in the wild type MEF cells. In contrast, almost no IL-8 promoter activity was observed in IKK1-, IKK2-and NEMOdeficient cells. Collectively, the above results suggest that synergistic action of IKK1, IKK2 and NEMO is required for activation of IL-8 promoter by K13.
Inhibition of K13-induced IL-8 promoter activity by genetic and pharmacological inhibitors of the classical NF-kB pathway K13 activates the classical NF-kB pathway via phosphorylation of IkBa, which leads to its ubiquitination and subsequent degradation via proteasome . Therefore, we tested whether phosphorylationresistant mutants of IkBa can block K13-induced IL-8 promoter activity. As shown in Figure 4b , K13-induced IL-8 promoter activity was completely blocked by a phosphorylation-resistant mutant of IkBa (IkBaSS32/ 36AA) in which the two critical N-terminal serine residues have been mutated to alanine. Similarly, a super-repressor form of IkBa, which lacks the Nterminal 36 amino acids (DIkBa), effectively blocked K13-induced IL-8 promoter activation (Figure 4b ). IL-8 production by K13 was also effectively blocked by siRNA-mediated downregulation of RelA/p65 expression, while siRNA-induced silencing of p100 was without significant inhibitory effect (Figure 4c and d) .
Next we sought to determine whether pharmacological inhibitors of the NF-kB pathway may be used to block K13-induced IL-8 promoter activation. Arsenic compounds are believed to block the NF-kB pathway by inhibiting the IKK complex (Kapahi et al., 2000; Roussel and Barchowsky, 2000) . We have previously shown that arsenic trioxide, phenylarsine oxide (PAO) and arsenic acid and are potent inhibitors of K13-induced NF-kB activation (Matta et al., 2003) . As such, we tested the ability of the above compounds to block K13-induced IL-8 promoter activity. As shown in Figure 4e , K13-induced IL-8 promoter activation was effectively blocked by all three arsenic compounds. 
K13 induces IL-8 via NF-jB pathway Q Sun et al
It has been reported that the ERK pathway may activate IL-8 transcription in an NF-kB-independent fashion (Holtmann et al., 1999) . We used PD98059, a specific inhibitor of the ERK pathway, to test its involvement in K13-induced IL-8 promoter activation. Unlike arsenic compounds, PD98059 had no inhibitory effect on K13-induced IL-8 promoter activity (Figure 4e ). Taken together, the above results suggest that NF-kB pathway plays a crucial role in K13-induced IL8 promoter activation and genetic and pharmacological inhibitors of the NF-kB pathway may have a role in the treatment of diseases in which HHV8-induced IL-8 induction plays a pathogenic role.
Role of JNK/AP1 pathway in K13-induced IL-8 promoter activation
The ability of K13 to activate the JNK/AP1 pathway is controversial. We have previously reported that K13 fails to activate the JNK pathway (Chaudhary et al., 1999a) . However, a recent study suggested that overexpression of a K13-EGFP fusion protein could strongly activate JNK pathway and AP1 DNA binding and transcriptional activities and JNK/AP1 pathway plays an important role in K13-induced activation of the IL-6 promoter . Since AP1/JNK1 pathway is also known to play a role in IL-8 transcriptional activation (Hoffmann et al., 2002) , we decided to recheck the ability of K13 to activate the AP1/JNK pathway and its involvement in IL-8 transcriptional activation. We began by testing the ability of K13 to activate the JNK pathway using a luciferasebased reporter assay in which luciferase expression is driven by JNK-mediated phosphorylation of the activation domain of transcription factor c-Jun fused to the GAL4 DNA-binding domain. TRAF6, a known activator of this pathway, was included as a positive control . Consistent with our published study (Chaudhary et al., 1999a) , overexpression of K13 failed to activate c-Jun transcriptional activity while TRAF6 readily did so (Figure 5a) . Similarly, K13 failed to activate a luciferase reporter construct containing AP-1-binding sites (Figure 5b ). We also examined whether K13 induces the binding of transcription factors to the AP-1 site present in the IL-8 promoter. As shown in Figure 5c , nuclear extracts from empty vector-expressing K562 cells demonstrated some baseline proteinbinding activity to the AP-1 site. However, there was no increase in the AP-1-binding activity when nuclear extracts from K13-expressing K562 cells were used. Nuclear extracts from K562 cells treated with TNFa and phorbol 12-myristate-13-acetate (PMA), two known activators of the JNK/AP-1 were used as positive controls and, as expected, demonstrated significant increase in AP-1 DNA-binding activity (Figure 5c ). Essentially, similar results were obtained when nuclear extracts from K13-expressing 293T cells were used (Figure 5d) . Collectively, the above results support the conclusion that K13 does not activate the JNK/AP-1 pathway.
The cis-elements for NF-kB and AP-1 are located in close proximity within less than 200 bp on the IL-8 promoter and NF-kB and AP-1 transcription factors are known to form a higher order nucleoprotein enhancesome complex on the IL-8 promoter that facilitates maximal gene transcription (Hoffmann et al., 2002) .
While the above results demonstrate that K13 does not activate the JNK/AP-1 pathway, it is conceivable that the baseline AP-1 activity present in the cells contributes to K13-induced IL-8 promoter activation by interacting with K13-induced NF-kB transcription factors. To test this hypothesis, we next examined the ability of K13 to activate an IL-8 promoter containing a 2 bp mutation in the AP-1-binding-site (IL-8-mAP1-Luc) (Wu et al., 1997) . As shown in Figure 5e , the IL-8-mAP1-Luc mutant demonstrated significantly reduced basal and maximal IL-8 promoter as compared to the wild-type IL-8-Luc promoter. However, unlike the IL8-mNF-kBLuc promoter, expression of K13 led to a significant (approximately 40-fold) increase in the activity of the IL8-mAP1-Luc promoter above that observed upon expression of an empty vector (Figure 5e ). Collectively, the above results demonstrate that while NF-kB-binding site is absolutely required for inducible IL-8 promoter activation by K13, AP-1 element contributes to the maximal activation of the IL-8 promoter by K13 but is not required for the inducibility of response.
SP600125 is a small molecular inhibitor of the JNK pathway (Bennett et al., 2001) . It has been reported that, at 5 mM, SP600125 specifically inhibits TNFa-and PMA-induced JNK activity in 293 cells without effect on the activity of other serine/threonine kinases, such as p44/p42, p38, IKKa, IKKb and PKC isoforms (Jiang et al., 2003) . Therefore, we tested the effect of SP600125 on K13-induced IL-8 promoter activation in 293 cells. As shown in Figure 5f , we failed to observe any inhibitory effect of 5 mM SP600125 on K13-induced IL-8 promoter activation. A partial inhibition of K13-induced IL-8 promoter activation was observed with 10 mM SP600125, which could reflect inhibition of baseline JNK/AP-1 activity or a nonspecific inhibitory effect on related serine/theronine kinases.
Discussion
IL-8 upregulation has been documented in several human cancers, including breast cancer, pancreatic cancer, melanomas, non-small-cell lung cancer and colon cancer (Smith et al., 1994; Ueda et al., 1994; Yokoe et al., 1997; Singh et al., 1999; Le et al., 2000) . IL-8 is a potent chemotactic factor for neutrophils and is also known to promote tumor angiogenesis (Sparmann and Bar-Sagi, 2004) . Consistent with the above roles, elevated production of IL-8 has been associated with increased tumor vascularization, metastases and overall adverse prognosis for a number of human cancers (Ueda et al., 1994; Nurnberg et al., 1999; Singh et al., 1999) . KS lesions are characterized by dense vascularization and infiltration by inflammatory cells, features consistent with the angiogenic and chemotactic properties of IL-8. A role for IL-8 production in the pathogenesis of KS is also supported by studies showing elevated IL-8 serum levels in KS patients as compared with matched controls and the ability of IL-8 antisense oligonucleotides to inhibit KS cell growth in a dose-dependent fashion (Masood et al., 2001) . Finally, infection with HIV-1 greatly increases the risk for the development of KS and IL-8 has been reported to stimulate HIV-1 replication (Lane et al., 2001) . Thus, IL-8 may contribute to the pathogenesis of KS via both direct and indirect mechanisms.
IL-8 expression is induced by a wide variety of proinflammatory stimuli, including tumor necrosis factor, interleukin-1, bacterial and viral infection and cellular stress (Hoffmann et al., 2002) . It has been also reported that KSHV infection of endothelial cells induces IL-8 production, which plays a crucial role in the angiogenic phenotype developed by KSHV-infected endothelial cells in culture and upon implantation into SCID mice (Lane et al., 2002) . However, KSHV genes and signaling pathways involved in IL-8 induction have not been fully characterized. Although HHV8 genome encodes for homologs of several chemokines and cytokines, none of them are expressed in cells latently infected with this virus (Schulz, 1998) . In contrast, HHV8-encoded vFLIP is expressed in latently infected KS spindle cells and, therefore, may play a pivotal role in the upregulation of IL-8 production seen in association with HHV-8 infection (Schulz, 1998) . ) were transfected in duplicate with the indicated constructs (500 ng) along with a fusion-transactivator plasmid containing yeast GAL4 DNA-binding domain fused to transcription factor c-Jun (pFA-cJun) (50 ng), a reporter plasmid encoding the luciferase gene downstream of the GAL4 Upstream Activating sequence (pFR-luc) (500 ng), as well as a RSV/LacZ (beta-galactosidase) reporter construct (75 ng). After 40 h cell extracts were prepared and used for the measurement of luciferase and b-galactosidase activities. Luciferase activity was normalized relative to the b-galactosidase activity to control for the difference in transfection efficiency. The values shown are averages (mean7s.e.) of one representative experiment out of three in which each transfection was performed in duplicate. (b) K13 fails to activate an AP-1-driven luciferase reporter construct. 293EBNA cells were transfected with the indicated expression constructs along AP1-luc and pRSV/LacZ reporter constructs and AP1 luciferase activity measured as described in Materials and methods section. (c) K13 fails to induce AP-1 DNA-binding activity in K562 cells. EMSA was performed using nuclear extracts from an empty vector-and K13-expressing K562 cells and a radiolabeled oligo-duplex derived from AP-1 site present in the IL-8 promoter. Nuclear extracts from treated K562 cells treated with TNFa (10 ng/ml) and PMA (50 ng/ml) were included as positive controls. Competition with excess cold nonspecific and AP-1-specific oligo-duplexes were used to demonstrate the specificity of the AP1 complex. 
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The transcriptional regulation of IL-8 production has been extensively characterized and transcription factor NF-kB is believed to play a central role in this process (Hoffmann et al., 2002) . Consistent with the published literature, in this study we demonstrate that vFLIP K13-induced IL-8 promoter activation is also dependent on the activation of the classical NF-kB pathway. This conclusion is supported by the following results. First, E8 and MC159, two vFLIPs which lack the ability to activate the NF-kB pathway failed to activate the IL-8 promoter. Second, IL-8 promoter activation by K13 mutants correlated with their ability to activate the classical NF-kB pathway. Third, K13-induced IL-8 transcriptional activation requires an intact NF-kBbinding site in the IL-8 promoter. Finally, genetic and pharmacological inhibitors of the classical NF-kB pathway can effectively block K13-induced IL-8 promoter activation.
In addition to the NF-kB-binding site, the core IL-8 promoter also contains binding site for AP-1 (activating protein 1) transcription factor (Hoffmann et al., 2002) . However, unlike the NF-kB site, the AP-1 site is believed not be essential for inducible activation of IL-8 transcription, but is instead believed to contribute to maximal gene expression (Wu et al., 1997; Hoffmann et al., 2002) . Consistent with above, in this study we have found that while mutation of the AP-1-binding site in the IL-8 promoter significantly reduced the basal and maximal reporter activities, there was significant residual transcriptional activation by K13 and mutation of AP-1-binding site had only a minimal effect on inducible activation of the IL-8 promoter by K13 (i.e. fold increase over vector-transfected cells). Thus, while the basal level of AP-1 activity present in the cell might synergize with K13-induced NF-kB pathway to maximally activate IL-8 transcription, our results do not support the model that K13 activates IL-8 transcription via upregulation of AP-1 activity. Consistent with the above hypothesis, K13 failed to activate the JNK pathway as measured by AP1 and c-Jun transcriptional assays or increase the DNA-binding activity on the AP-1 site present in the IL-8 promoter. Collectively, our results support the model that K13 activates the IL-8 promoter by inducing nuclear translocation of the classical NF-kB subunits (i.e. p65, c-Rel and p50), which subsequently interact with the basal level of AP-1 transcription factor present in the nucleus to form a multisubunit transcriptional activation complex on the IL-8 promoter. Such a complex, termed transcriptional enhanceosome, has been previously described for IFNb, another virus-inducible cytokine (Falvo et al., 2000) and has been postulated to play a role in IL-8 transcriptional regulation (Hoffmann et al., 2002) .
IL-8 is known to bind to two types of receptors called CXCR1 and CXCR2, respectively. Both types of IL-8 receptors are expressed in normal endothelial cells as well as in KS cell lines and primary tumor samples (Masood et al., 2001) . HHV8 is also known to encode a constitutively active G-protein-coupled receptor (vGPCR), which is capable of transforming cells and inducing KS-like disease in transgenic mice (Yang et al., 2000; Bais et al., 2003) . In this context, it is interesting to note that IL-8 acts as a ligand and enhances signaling via vGPCR (Gershengorn et al., 1998) , which, in turn, upregulates IL-8 production (Masood et al., 2001 ). Thus, K13-mediated IL-8 production may act in concert with vGPCR in the pathogenesis of KS. Selective inhibitors of K13-induced IL-8 production, such as inhibitors of the classical NF-kB pathway, may have a role in the treatment of HHV8-associated KS.
Materials and methods
Plasmids, cell lines and reagents
Plasmids containing pcDNA3-K13-Flag, pcDNA3-MC159L and pcDNA3-E8-Flag, pRSV/LacZ and 293T cells have been described previously. Luciferase reporter constructs containing wild-type IL-8 promoter and mutant derivatives were obtained from Dr Andrew Keates (Harvard Medical School) and have been described previously (Wu et al., 1997) . Retrovirus constructs containing C-terminal Flag epitope-tagged HHV8 vFLIP (K13-Flag) were generated in MSCVneo and MIGR1-based retroviral vectors (Pear et al., 1998) and amphotropic viruses generated and used for infection as described previously . The IKKaÀ/À and IKKbÀ/À mouse embryonic fibroblast cells were generated in Dr Inder Verma's laboratory (Li et al., 1999a, b) and IKKg/NEMOÀ/À cells were generated in Dr Michael Karin's laboratory (Makris et al., 2000) . These cells were kindly provided by Dr Richard Gaynor and were maintained in DMEM supplemented with 10% FBS. Jurkat cells were cultured in RPMI medium supplemented with 10% FBS and selected in the presence of 1500 mg/ml of G418 (Invitrogen). 293T and Hela cells were grown in DMEM with 10% FBS and Hela cells were selected in the presence of 1 mg/ml of G418 . Human umbilical vein cells (HUVEC) cells were obtained from Cambrex (Baltimore, MD, USA) and grown in EGM-2 medium (Cambrex). Arsenic trioxide, arsenic acid and PAO was purchased from Sigma. SP600125 and PD9805 were purchased from Calbiochem.
Electrophoretic mobility shift assay Electrophoretic mobility shift assay was performed essentially as described previously , using oligonucleotide duplexes containing either wild-type NF-kB-binding site (sense strand, 5 0 GATCCGTGGAATTTCCTCTG 3 0 ) present in the IL-8 promoter or a mutant NF-kB-binding site (sense strand, 5 0 GATCCGTTAACTTTCCTCTG 3 0 ). Oligonucleotide duplexes (sense strand, 5 0 GATCGTGATGACTCAGGT3 0 ) containing an AP1 site derived from IL-8 promoter was used for measuring AP-1-binding activity. Antibodies against p50, p65, RelB and c-Rel were purchased from Santa Cruz Biotechnology. Antibody against p52 was purchased from Upstate biotechnology Luciferase reporter assay 293T cells were transfected in duplicate in a 24-well plate with the various test plasmids along with an IL-8/luciferase reporter construct (10 ng/well) and a pRSV/LacZ (b-galactosidase) reporter construct (75 ng/well) using calcium phosphate transfection protocol as described previously. Cells were lysed 36-48 h later and extracts were used for the measurement of firefly luciferase and galactosidase activity. Luciferase activity was normalized relative to the galactosidase activity to control for the difference in the transfection efficiency. Essentially, a similar procedure was used for measurement of AP-1 reporter activity using an AP1-Luc reporter plasmid (Stratagene). Luciferase reporter assay in MEF cells was conducted essentially as described previously (Sun et al., 2005) .
Western blot
Western blot analysis was performed essentially as described previously . Primary antibodies used in these experiments were: p52 (mouse monoclonal, Upstate Biotechnology), p65 (rabbit polyclonal, Santa Cruz Biotechnology) and Actin (mouse monoclonal, Sigma).
siRNA oligonucleotides siRNA oliginucleotides with two thymidine residues (dTdT) at the 3 0 -end of the sequence were designed to p65 (sense, 5 0 -GCCCUAUCCCUUUACGUCAdTdT-3 0 ), p100 (sense, 5 0 -GACCUAUCCCACUGUCAAGdTdT-3 0 ) and Lamin A/C (sense, 5 0 CUGGACUUCCAGAAGAACAdTdT-3 0 ), along with their corresponding antisense oligonucleotides. The RNA oligonucleotides were synthesized at RNA Oligonucleotide Synthesis Core facility, UT Southwestern Medical center. siRNA oligonucleotides (80 nM) were transfected by using calcium phosphate as described previously (Sinha and Chaudhary, 2004) .
ELISA
Human IL-8 was measured in the cell culture supernatant using an IL-8 ELISA kit (Pharmingen) and following the recommendations of the manufacturer.
